What is a potential risk of using LABA for daily asthma prevention?

The correct answer highlights that the use of Long-Acting Beta-Agonists (LABAs) for daily asthma prevention may mask poorly controlled persistent asthma. LABAs function by providing prolonged bronchodilation, which can lead to a false sense of control over asthma symptoms. When a patient relies on a LABA without addressing the underlying inflammation—a primary issue in asthma management—they may not notice the worsening of their condition. This can delay necessary treatment adjustments, as the patient might not experience typical symptoms that signal the need for better management, thus putting them at risk for an exacerbation.

In the context of asthma management, it’s essential to combine a LABA with an inhaled corticosteroid (ICS) to provide comprehensive control of both the airway inflammation and bronchoconstriction. Sole dependence on LABAs can be particularly dangerous because while patients may feel better initially, it does not mean their asthma is well-controlled, which could lead to serious health risks and potentially life-threatening situations if exacerbations occur.

The other options suggest different side effects or consequences of LABA use, but they do not directly address the critical issue of symptom masking, making the first option the most relevant concern in the context of daily asthma prevention.